


Virginia Neonatal Abstinence Syndrome Active Case Reporting

Year to Date Reporting Summary
January 1, 2020 through September 30, 2020

| | |
|--|------------|
| Total NAS Cases Reported† | 287 |
| Missing | 0 |
| In State | 272 |
| Out of State | 15 |
| Sex of Infant† | |
| Missing | 5 |
| Females | 140 |
| Males | 141 |
| Unknown | 1 |
| Race of Infant† | |
| Missing | 22 |
| Black/African American | 18 |
| White | 145 |
| Other | 2 |
| Unknown | 3 |
| Hispanic/Latino | 3 |
| Severity of NAS Signs | |
| Mild signs requiring non-pharmacologic treatment | 154 |
| Severe clinical signs requiring pharmacotherapy | 133 |
| Other Supportive Elements for Diagnosis‡ | |
| Maternal history of substances known to cause NAS | 272 |
| Positive maternal screening test for substances known to cause NAS | 195 |
| Positive neonatal screening test for substances known to cause NAS | 221 |
| No other supportive elements for diagnosis | 6 |

| | |
|---|-----|
| Source of Exposure‡ | |
| Medication-assisted treatment (MAT) | 215 |
| Legal prescription of opioid pain reliever | 22 |
| Legal prescription of a non-opioid | 17 |
| Prescription opioid obtained without prescription | 40 |
| Non-opioid prescription obtained without prescription | 20 |
| Heroin | 37 |
| Other non-prescription substance (e.g. illicit drugs other than heroin) | 72 |
| No known exposure but clinical signs consistent with NAS | 2 |
| Other (e.g. SSRIs, another drug used in the polysubstance instances) | 24 |



†Data is reported as missing here if the clinician filing the case report omitted a response to this field in the data collection form.

‡More than one option may have been selected, so totals may sum to >100% of overall case total.

Note: Cases in system where reporter indicated that there were no signs or symptoms of withdrawal were omitted from this case report, as they do not meet the standard case definition in use.

*This report includes data recorded as of March 18, 2021.